Delving into the Latest Updates on GVAX myeloma vaccine(Cell Genesys) with Synapse

Overview

Basic Info

Drug Type

Therapeutic vaccine

Synonyms-

Target-

Mechanism

Immunostimulants

Therapeutic Areas

NeoplasmsImmune System DiseasesCardiovascular Diseases+ [1]

Active Indication

Multiple Myeloma

Inactive Indication-

Originator Organization

Cell Genesys, Inc.

Active Organization

Aduro BioTech, Inc.

Inactive Organization

Cell Genesys, Inc.

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

This study seeks to determine whether addition of an allogeneic myeloma vaccine can augment clinical responses to lenalidomide in patients with near complete remission (nCR), or complete remission (CR) leading to a significant improvement in progression-free survival.This main objective of this study is to compare the 2-year progression free survival of patients with multiple myeloma in CR or nCR, treated with lenalidomide plus an allogeneic myeloma vaccine in combination with lenalidomide (with or without Prevnar vaccine) or versus placebo in combination with lenalidomide (control arm).

Start Date23 Sep 2019

Sponsor / Collaborator

The Sidney Kimmel Comprehensive Cancer Center

[+2]

NCT00116441 / CompletedPhase 1/2

Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma: The Use of Autologous Tumor Cells With an Allogeneic GM-CSF Producing Cell Line

The purpose of this study is to evaluate the safety and efficacy of vaccination with autologous myeloma cells and an allogeneic granulocyte-macrophage colony stimulating factor (GM-CSF) producing cell line.

Start Date01 Oct 2000

Sponsor / Collaborator